Three patients are reported to have suffered significant vision loss following “stem cell” treatment in a Florida clinic
A brief report, published in the New England Journal of Medicine (NEJM 2017;376:1047-53), has highlighted three cases of severe vision loss in elderly female patients following autologous “stem cell” treatment. The report, from the Bascom Palmer Eye Institute, University of Miami, Florida, follows the management of three cases of vision loss in patients with age-related […]Read full story
“Name and shame” clinical trial tracker, launched by University of Oxford researchers, highlights worst and best trial sponsors
A new automated tool, the “Trial Tracker”, has been launched by two academic researchers working at the Evidence-Based Medicine Data Lab, University of Oxford, UK. The tool provides an automated software algorithm designed to identify clinical trial sponsors with the best and worst record for sharing trial results. The underlying premise is that a failure […]Read full story
Phase IIa trial recruits first patient for novel therapy directed towards treatment of Stargardt’s disease.
A Phase IIa human study, sponsored by Acucela Inc., based in Seattle, Washington, has announced the recruitment of its first patient to evaluate emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease. The experimental small molecule treatment, a visual cycle modulator, will be tested in a multicenter, randomized, blinded study to investigate the […]Read full story